This was similarly appreciated in the International Neoadjuvant Melanoma Consortium (INMC) pooled analysis of neoadjuvant BRAF/MEK inhibitor use in patients with clinical stage III melanoma, showing that achieving a pCR, but not a pPR, correlated with improved RFS9,22,23. Here, BRAF is linked to melanoma.